NEW HAVEN, Conn., July 29, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (the “BBB”) announced today that it has filed its unaudited quarterly financial statements and management’s discussion and analysis for the period ended May 31, 2022. All are available under the Company’s profile on SEDAR and on the Company’s website at www.bioasis.us/investors/.
Bioasis Announces Filing of Its First Quarter Financial Statements and MD&A
Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.
